Skip to main content
. 2022 Sep 20;9:981001. doi: 10.3389/fmed.2022.981001

Figure 3.

Figure 3

Kaplan-Meier survival curves of hepatocellular carcinoma patients treated with anti- PD-1 were analyzed in those with immune- related adverse events according to BMI levels. Among the irAEs+ patients, overweight patients had longer PFS than non-overweight patients, and no disease progression was observed in the three overweight patients after anti-PD-1 treatment (log-rank test). BMI, body mass index. non-over weight BMI ≤ 24.9, over weight BMI > 24.9.